Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, ...
The US Food and Drug Administration (FDA) and the medtech industry have agreed to commitment letter language for the Medical ...
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
The US Food and Drug Administration (FDA) on Friday outlined a set of proposed reforms to advance modern manufacturing ...
The US Food and Drug Administration (FDA) recently issued two warning letters to companies for marketing medical devices ...
India’s National Pharmaceutical Pricing Authority (NPPA) has announced price reductions for more than 30 drugs and biological ...
The Trump administration has released its latest unified agenda, laying out the proposed and final rules its agencies plan to ...
Industry experts say the draft commitment letter for the next Medical Device User Fee Amendments (MDUFA VI) program negotiated by the US Food and Drug Administration (FDA) and the medtech industry ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is ...
In the draft version, FDA said sponsors should plan to characterize the durability of response for their drug product, the recommended inter-dose interval for maintenance of effect, and the safety and ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results